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The following case was presented 26 September 2016 as part of the Clinical-Pathological 
conference chaired by Anna F. Dominiczak and Rhian M. Touyz at the 26th Scientific Meeting of 
the International Society of Hypertension. Hyun-Jung Lee presented the case and the discussion 
was led by Hae-Young Lee. 
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Case Introduction 
A 47-year-old female visited the emergency room in March 2006. Her main complaint was 
dyspnea, which began two months prior. She was a previously healthy woman, but after upper 
respiratory infection two months before, she developed symptoms of cough, myalgia, epigastric 
pain, and dyspnea of NIHA functional class II to III with intermittent chilling. She was managed at 
the local clinic for asthma but there was no improvement in symptoms. 
 
One month prior to the emergency room visit, she had a procedure for anal hemorrhoids and 
bled severely and received transfusion. Three days before visiting the emergency room, cough 
and dyspnea deteriorated. She went to the local hospital, was diagnosed with heart failure, and 
was referred to the emergency room. There was nothing notable in her medical history. She was 
a housewife, non-smoker and did not drink alcohol. She had nothing of interest in her family 
history. 
 
On interview, she had general weakness and easy fatigability. She also had anorexia, 
indigestion and some weight loss. She continued to have cough and dyspnea, which aggravated 
on supine position and on exertion. On physical examination, she had normal blood pressure 
(BP) at 129/86 mmHg. Heart rate was slightly elevated at 113 beats per minute and her 
breathing was rather fast at 22 times per minute. Body temperature and oxygen saturation were 
normal. Her height was 161 centimeters and her weight was 67 kilograms; she was overweight. 
 
The patient was slightly anemic and icteric on examination. She was not dehydrated. On 
auscultation, coarse breath sounds with crackles in the right lower lung field and rapid heartbeat 
with a soft systolic murmur could be heard. Abdomen was soft and flat without any tenderness 
and no visible edema or cyanosis. Arterial blood gas analysis done at room air indicated normal 
O2 pressure and signs of hyperventilation. She had slight leukocytosis with a normal segmented 
fraction. 
 
Total bilirubin was elevated at 2.6 mg/dL. Liver enzymes were elevated at aspartate 
transaminase 930 units per liter and alanine transaminase 1,868 units per liter. Prothrombin time 
(INR) was elevated at 1.59 and her urine was rather concentrated and albuminuria was 2 
positive. B-natriuretic peptide (BNP) level was 2,002 picograms per mL. Glycosylated 
hemoglobin (HbA1c) level was 6.8% and fasting blood sugar was 142 mg/dL, and later, she was 
newly diagnosed with diabetes mellitus. Thyroid function was normal and hepatic serology was 
normal.  
 
Initial chest x-ray showed cardiomegaly and pulmonary congestion with right pleural effusion 
(Figure 1A). The initial electrocardiogram (ECG) showed sinus tachycardia with ST elevation at 
V1 to V3 and ST depression at V6 suggesting a left ventricular hypertrophy (Figure 2). Her initial 
echocardiogram was as follows; she had dilated LV cavity with an end-systolic dimension of 61 
millimeters and an end-diastolic dimension of 72 millimeters and wall thickness was normal. 
There was global hypokinesia with secondary mitral regurgitation (MR) due to tethering, and 
ejection fraction was decreased at 28% (Video 1-4). 
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A myocardial SPECT was performed to check for cause of heart failure (Figure 3). There was no 
significant perfusion decrease suggesting ischemic heart disease. 
 
Differential Diagnosis 
ECG showed ST elevation and less focal change, but there was global hypokinesia and no 
specific regional wall motion abnormality. We ruled out coronary artery disease by SPECT. 
Thus, the initial assessment was dilated cardiomyopathy aggravated by a cold with congestive 
hepatomegaly and newly diagnosed diabetes mellitus.  
 
She was admitted to the ward on dobutamine support and parenteral diuretics. Her symptoms 
improved after hemodynamic stabilization, weight reduction of 4 kg with diuretics, and addition of 
ACE inhibitor and beta blocker. She was discharged after 1 week; at time of discharge, her BP 
was 90/74 mmHg and her heart rate was still high at 107 BPM. Medication at discharge was 
typical for heart failure management: carvedilol 6.25 mg twice daily, captopril 12.5 mg three 
times daily, and furosemide 40 mg daily. As you can see, we had started beta-blocker treatment 
without alpha blockade. 
 
 
Was it Possible to Suspect Pheochromocytoma? 
 
Dr. Hae-Young Lee: A point of interest is how this patient was safe with inotropics. We 
all know that sympathomimetics may stimulate catecholamines, which may be very 
harmful to the patient. However, desensitization of the cardiovascular system to 
catecholamines after long-term exposure to high circulating levels may contribute to a 
relatively normal BP and blunted response to sympathomimetics1. Regardless, with this 
presentation, could you suspect pheochromocytoma in this patient? 
 
Prof. Anna Dominiczak: Clearly, very difficult; as you told us at the beginning, 
pheochromocytoma is a great mimic. I think you discovered this patient at a time when 
this great mimicry was already very advanced; I presume this pheochromocytoma had 
been present for quite a while and the excessive catecholamines caused destructive 
changes of cardiomyocytes leading to dilated cardiomyopathy. As the BP was completely 
normal or low, you didn’t measure the catecholamine levels. 
 
 
The Case Continues 
At the outpatient clinic, the patient’s BP and heart rate normalized and stayed stable for two 
years on carvedilol 6.25 mg twice daily, losartan 50 mg daily and torasemide 5 mg daily. In the 
second year, her BP started to increase to 150/100 and long acting nifedipine GITS was added. 
Also, blood sugar levels remained marginally high at fasting blood glucose 180 mg/dL and 
HbA1c 6.8% despite lifestyle modifications, therefore, metformin was added. With addition of 
medication, BP and blood glucose levels were controlled once more. 
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ECG and chest x-ray were conducted at the two year follow up. There is diffuse T inversion on 
the ECG (Figure 2B) but her chest x-ray shows improvements with disappearance of 
cardiomegaly and pulmonary congestion (Figure 1B). Follow up echocardiography was done 
and LV cavity size was normalized, with an end-systolic dimension of 24 millimeters and an end-
diastolic dimension of 46 millimeters. Ejection fraction recovered from 28% to 73%. Secondary 
MR disappeared and ejection fraction was normalized but apical akinesia was still present 
(Video 5-8). 
 
At third year of follow up at the outpatient clinic, her BP, heart rate and blood sugar levels 
started to slowly rise. BP medication was changed to single-pill combination of 
amlodipine/valsartan 5mg/160mg. Sitagliptin was added and later the dose was increased. 
Carvedilol was initially discontinued due to concerns that it might aggravate hyperglycemia, but 
then BP and heart rate rose and bisoprolol 2.5 mg daily was added again.  
 
BP was stable with medication but blood glucose levels continued to rise. In the fifth year, her 
glucose levels started increasing very steeply and HbA1c suddenly rose to 9.3%. Glimepiride 
was added. After three months, HbA1c level decreased once more to 7.3%. During this time, BP 
was stable. 
At five years, we performed another follow up. Her ECG was totally normalized (Figure 2C) and 
the chest x-ray was normal. Echocardiography continued to show normal left ventricular size and 
systolic function, and apical akinesia was also resolved (Video 9-12). 
 
At the sixth year of follow up, BP started rising once more to 150/90 mmHg. She was on 
amlodipine, valsartan, and carvedilol; Thiazide and spironolactone were added and the beta 
blocker dosage of carvedilol was increased to 25 mg twice daily. Meanwhile, HbA1c levels were 
stable on metformin, sitagliptin and glipizide but rather high at 7.7%.  
 
 
Hypertension in Pheochromocytoma 
As you can see, her BP continued to rise, but was maintained under control with addition of 
medication, making it hard to suspect secondary hypertension. When screening for secondary 
hypertension, pheochromocytoma is always one of the first things to rule out. However, 
pheochromocytoma is an uncommon cause of secondary hypertension. Pheochromocytoma is 
diagnosed in 0.2% of all hypertension patients, and even in resistant hypertension, the 
prevalence is only 1%2. On the other hand, most of the pheochromocytoma patients show 
hypertension, either sustained or paroxysmal. 
 
There are subtle differences in the pattern of hypertension based on the main secreted 
catecholamine. In the norepinephrine dominant type, peripheral vascular resistance is mainly 
increased, resulting in increase of both SBP and DBP, and patients usually show sustained 
hypertension. However, in the epinephrine dominant type, cardiac output is mainly increased 
and episodic symptoms are more common, and SBP is increased while there is no major effect 
on DBP due to beta 2-adrenoceptor-mediated vasodilator actions3. In the majority, paroxysmal 
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hypertension occurs at least weekly and generally lasts from several minutes to one hour4. In the 
rare dopamine dominant types, patients often show normotension or even hypotension. 
 
Time to time at the outpatient clinic, our patient complained of headache. She did not measure 
home BP and every time she visited the clinic, blood pressures were within reference ranges. It 
was not possible to determine whether headaches were an episodic symptom of 
pheochromocytoma.  
 
A notable point in the case is that the patient continued to receive beta blockers to control BP 
and heart rate, in the absence of alpha blockade. Theoretically, in pheochromocytoma, beta 
blockers should never be initiated until there is sufficient alpha-adrenoceptor blockade, because 
the inhibition of beta 2-adrenoceptor mediated vasodilatory actions may cause enhanced 
vasoconstrictor responses leading to further increase in BP. Thus, cardioselective beta blockers 
are preferred. Carvedilol’s alpha blocking potential is much less than its beta blocking efficacy. 
 
 
Discovering Pheochromocytoma 
At the seventh year of follow-up, glycemic levels started to deteriorate despite intensification of 
oral hypoglycemic agents. Carvedilol was discontinued due to concern of its aggravating 
hyperglycemic effects. In the eighth year, despite full dose of metformin, sitagliptin and 
sulfonylurea, HbA1c rose to 9.4%, and the endocrinology department was consulted for a 
second opinion. On their recommendation, insulin was started (Figure 5). BP rose to 144 / 84 
mmHg, and heart rate rose to 103 bpm, after discontinuation of beta blocker. 
 
At that time, the urinalysis and microscopy, performed as part of her diabetes follow-up, showed 
appearance of albuminuria, and ominously, microscopic hematuria at 10-19/HPF. For further 
work up of intermittent microscopic hematuria, urine cytology was done and found to be 
negative, and abdomen computed tomography (CT) was done. On the abdominal CT, 
unexpectedly, a huge mass at the right adrenal gland was discovered (Figure 4). The lobulating 
mass was around 7 x 7 cm, and showed good enhancement with internal cystic change and 
suspicious focal hemorrhage, which was consistent with pheochromocytoma.  
 
Hormone tests were done, and serum metanephrine and normetanephrine levels were elevated, 
as well as urine catecholamine levels. Renin and aldosterone levels were also elevated. Whole 
body PET showed a hypermetabolic mass in the right adrenal gland, and otherwise no distant 
metastasis. 
 
Thus, the patient was diagnosed with pheochromocytoma. Hormone evaluation showed greatly 
elevated serum and urine catecholamines (Table 1). Especially, metanephrine and epinephrine 
levels were elevated, indicating a predominantly adrenalin secreting type of pheochromocytoma. 
Alpha blockade with doxazosin at 2 mg twice daily was started, and she was referred for 
surgery. 
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Discussion continues 
Dr. Hae-Young Lee: In her clinical course, after the first episode of heart failure, heart 
function normalized on echocardiography follow up. BP and heart rate were controlled 
marginally on oral medication, and responded to beta blockers. Diabetes mellitus 
progressed out of control despite full medication. After nine years of follow up, 
pheochromocytoma was incidentally diagnosed after computer tomography due to 
microscopic hematuria. At this point, I hope to ask your opinion, at what time could I have 
diagnosed pheochromocytoma earlier during nine years follow up? 
 
Prof. Anna Dominiczak: I think it is very difficult in this case because she did not 
really have prominent hypertension until very late. My question is, during observation of 
this patient, have you ever done ambulatory BP monitoring? Or home BP monitoring? 
This could have picked up things earlier. 
 
Dr. Hae-Young Lee: No, I did not think of doing ambulatory BP, and that is a good 
point, because she was on more than the usual two medications to control BP. 
 
Prof. Garry Jennings: I do not know when you could have made this diagnosis. 
You had to get lucky, I think. It's interesting, reflecting on the pharmacology of carvedilol 
that she was not hypertensive until you improved her ventricular function to the point that 
she could sustain an elevated BP. It was fortunate that a drug, which is predominantly a 
beta blocker with a little bit of alpha blockade, did not increase her BP further because 
she was predominantly secreting adrenalin. It has been a course which could have been 
very different, if it had been a different kind of pheochromocytoma. 
 
Dr. Saula Siddique: Two questions. You have had a lot of tests done but what was her 
fundoscopy like initially and on subsequent examinations? Also, at the initial emergency 
room tests, she showed elevated prothrombin time (INR) of 1.59; was it investigated? 
 
Dr. Hae-Young Lee: During her follow up, I did not think she was the typical 
hypertension or hypertensive heart failure patient and I did not send her for retinal 
examination. Initial INR was only mildly elevated at 1.59, and I thought this was part of 
congestive hepatomegaly. Prothrombin time was normalized after discharge. 
 
Dr. Eun Joo Cho: On her second examination at two years, there is a Q wave 
inversion in ECG and echocardiography shows apical aneurysm. There seems to be 
enough reason to perform a coronary angiography because she has diabetes and 
hypertension. Did she ever have angina symptoms, and did you check cardiac enzymes 
or ever perform the coronary angiography? 
 
Dr. Hae-Young Lee: Very good question. We often perform coronary angiography at the 
first presentation to investigate heart failure etiology, but in this case, the initial cardiac 
enzymes were completely normal. Also, her clinical response to heart failure 
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management was quite rapid. SPECT did not show signs of hypoperfusion. Based on 
these two findings, I ruled out the possibility of a coronary artery disease. 
 
Dr. Eun Joo Cho: Sometimes pheochromocytoma produce cortisol. During her 
course, did she ever develop any hypokalemia? 
 
Dr. Hae-Young Lee: No, as I used thiazide diuretics, I routinely checked electrolytes but 
she did not show hypokalemia or other derangements.  
 
Case Resolution 
It took nine years from first meeting this patient to the final diagnosis of pheochromocytoma. 
Diabetes progressed out of control during follow up, but after the operation her blood sugar 
levels totally normalized without any medication. Hypertension also totally disappeared. 
 
At this point, I would like to talk about diabetes in pheochromocytoma. Pheochromocytoma is 
one of the endocrine disorders with the highest prevalence of diabetes at 33% and impaired 
glucose tolerance at 50%5. For majority of patients, hypoglycemia is present but usually takes a 
milder course. The adrenaline dominant type has higher affinity for beta receptor and is 
therefore more potent in producing hyperglycemia. Beta receptors stimulate gluconeogenesis 
and alpha-2 receptors decrease insulin release, which are the main mechanisms of 
pheochromocytoma associated hyperglycemia. During her course, when her HbA1c rose to 
9.3%, I added sulfonylurea at only one tablet per day, and her HbA1c level decreased by two 
points. This is unusual, because usually, sulfonylurea only decreases HbA1c by 1%. This may 
have been related to rejuvenation of insulin release from the basal cell. 
 
After diagnosing pheochromocytoma, we started alpha blockade with doxazosin, and supplied 
sufficiently massive fluid resuscitation of six liters per day one day before the operation. Because 
the patient usually has volume constriction, hydration is very important to prevent hypotensive 
episodes during the operation. 
Regarding pre-operative alpha blocking, there is still debate over whether the nonselective alpha 
blocker phenoxybenzamine is better or the alpha1-selective blocker doxazosin is better6. One 
good point of phenoxybenzamine is better BP control, but phenoxybenzamine is not a familiar 
antihypertensive agent. On the other hand, doxazosin is familiar, and is known to be associated 
with less pronounced BP fluctuation during surgery7. In this case, we used doxazosin, but 
current standard of BP control for pheochromocytoma in my hospital is phenoxybenzamine.  
 
The pathology report for the resected right adrenal mass showed pheochromocytoma with 
portions of malignant change (Figure 6). After surgical removal of pheochromocytoma, diabetes 
and hypertension completely disappeared and the patient is off medication. 
 
 
Final Discussion Points 
Dr. Hae-Young Lee: I would like to ask the audience’s opinion on what the adequate 
preoperative alpha blockade strategy is between phenoxybenzamine and doxazosin? 
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Prof. Dominiczak: In our center, we would have used phenoxybenzamine because 
that is how it has always been done but I do not think there is any evidence that one is 
truly better than the other. It is quite good to lower BP preoperatively as you did. Maybe it 
does not matter which drug is used, it is important to control BP very carefully during 
surgery to avoid any big BP variations, both up and down.  
There is one additional question that just came to my mind. Was she ever pregnant 
before? There have been previous reports that occasionally pheochromocytoma comes 
to light during pregnancy, especially if there are any procedures such as a cesarean 
section.  
 
Hae-Young Lee: No. She had no experience of pregnancy. One year before heart 
failure elevation, she had surgery for hemorrhoid under local anesthesia, and there were 
no problems. 
 
 
Summary 
Final diagnosis was adrenalin dominantly secreting type of pheochromocytoma, which caused 
transient heart failure and diabetes mellitus. Through this conference, I hope you will keep in 
mind that pheochromocytoma has multiple faces, and to consider this possibility in unusual 
cases. 
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Tables 
Table 1. Hormone evaluation (Year 8) 
Hormones Measured values Normal Range 
Serum   
    Metanephrine  >20,000 pg/mL 90-130 pg/mL 
    Normetanephrine 16,877 pg/mL 100-2300 pg/mL 
24 hour urine   
    Epinephrine 1,219.4 ug 0-20 ug 
    Norepinephrine 490.9 ug 15-80 ug 
    Dopamine 174.7 ug 65-400 ug 
    Metanephrine 12,326.2 ug 52-341 ug 
    Normetanephrine 4,078.6 ug 88-444 ug 
    Urine VMA 25.7 mg, 28.9 ug/mg Cr 2-7 mg, 0-7 ug/mg Cr 
Renin 26.7 ng/mL/hr 1-2.5 ng/mL/hr 
Aldosterone 23.5 ng/dL 3-16 ng/dL 
Cortisol(S) 21.4 ug/dL  5-25 ug/dL 
DHEA-S 361 ng/mL 350-4300 ng/mL 
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Figures 
Figure 1. (A) Initial chest X-ray (Chest PA). (B) Chest PA at 2 years. 
Figure 2. (A) Initial electrocardiogram (ECG). (B) ECG at 2 years. (C) ECG at 5 years. 
Figure 3. Myocardial SPECT 
Figure 4. Abdomen imaging at 8 years. (A) CT. (B) MRI. 
Figure 5. Hemoglobin A1C levels during follow up, and concomitant medication with oral 
hypoglycemic and beta blockers. 
Figure 6. Pathology. (A) Gross specimen. (B) Malignant portion of the mass showing profound 
nuclear polymorphism and hyperchromasia, and absence of regular nest pattern. (C) Benign 
portion of the mass showing round nuclei and trabecular shaped cell nests. 
 
Videos 
Video 1-4. Initial echocardiogram. 
Video 5-8. Echocardiogram at 2 years. 
Video 9-12. Echocardiogram at 5 years. 
 
 
  
 11
References 
1. Bravo E, Fouad-Tarazi F, Rossi G, Imamura M, Lin WW, Madkour MA, Wicker P, 
Cressman MD, Saragoca M. A reevaluation of the hemodynamics of 
pheochromocytoma. Hypertension. 1990;15:I128-131 
2. Rimoldi SF, Scherrer U, Messerli FH. Secondary arterial hypertension: When, who, and 
how to screen? Eur Heart J. 2014;35:1245-1254 
3. Prejbisz A, Lenders JW, Eisenhofer G, Januszewicz A. Cardiovascular manifestations of 
phaeochromocytoma. J Hypertens. 2011;29:2049-2060 
4. Brouwers FM, Lenders JW, Eisenhofer G, Pacak K. Pheochromocytoma as an endocrine 
emergency. Rev Endocr Metab Disord. 2003;4:121-128 
5. Adlan MA, Bondugulapati LN, Premawardhana LD. Glucose intolerance and diabetes 
mellitus in endocrine disorders - two case reports and a review. Curr Diabetes Rev. 
2010;6:266-273 
6. Bruynzeel H, Feelders RA, Groenland TH, van den Meiracker AH, van Eijck CH, Lange 
JF, de Herder WW, Kazemier G. Risk factors for hemodynamic instability during surgery 
for pheochromocytoma. J Clin Endocrinol Metab. 2010;95:678-685 
7. Zhu Y, He HC, Su TW, Wu YX, Wang WQ, Zhao JP, Shen Z, Zhang CY, Rui WB, Zhou 
WL, Sun FK, Ning G. Selective alpha1-adrenoceptor antagonist (controlled release 
tablets) in preoperative management of pheochromocytoma. Endocrine. 2010;38:254-
259 
 
AB
AB
C

AB
45
6
7
8
9
10 OP
+ SU
+ Lantus
+ MFM
+ Sitaglip inc
inc
d/c CVD
+ Biso
Biso
à Nebi
à CVD
d/c CVD
d/c Sita
+ Pio
inc
Oral hypoglycemics
Beta-blockers
HbA1c
A B
C
